188 related articles for article (PubMed ID: 20386528)
1. Prognostic factors in patients treated with VEGF-targeted therapies.
Choueiri TK
Clin Adv Hematol Oncol; 2010 Feb; 8(2):92-3. PubMed ID: 20386528
[No Abstract] [Full Text] [Related]
2. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
4. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
5. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapy - point blank or single shot].
Rübben H
Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
[No Abstract] [Full Text] [Related]
7. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
8. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
9. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
12. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
13. Surgical resection of renal cell carcinoma after targeted therapy.
Thomas AA; Rini BI; Stephenson AJ; Garcia JA; Fergany A; Krishnamurthi V; Novick AC; Gill IS; Klein EA; Zhou M; Campbell SC
J Urol; 2009 Sep; 182(3):881-6. PubMed ID: 19616232
[TBL] [Abstract][Full Text] [Related]
14. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
15. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Iacovelli R; Alesini D; Palazzo A; Trenta P; Santoni M; De Marchis L; Cascinu S; Naso G; Cortesi E
Cancer Treat Rev; 2014 Mar; 40(2):271-5. PubMed ID: 24070900
[TBL] [Abstract][Full Text] [Related]
16. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
19. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Verzoni E; Lanocita R; Procopio G
Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
[No Abstract] [Full Text] [Related]
20. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
